Purchase by Mark Vignola of 743 shares of Terns Pharmaceuticals
TERN Stock | USD 6.44 0.64 9.04% |
About 62% of Terns Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Terns Pharmaceuticals stock suggests that many investors are alarmed at this time. Terns Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Terns Pharmaceuticals. Many technical investors use Terns Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Terns |
Filed transaction by Terns Pharmaceuticals Inc officer. General open market or private purchase of non-derivative or derivative security
Read at macroaxis.com
Terns Pharmaceuticals Fundamental Analysis
We analyze Terns Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Terns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Terns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Terns Pharmaceuticals is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Terns Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Terns Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Terns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Terns Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Terns Pharmaceuticals Related Equities
XFOR | X4 Pharmaceuticals | 2.63 | ||||
HOOK | Hookipa Pharma | 1.21 | ||||
DAWN | Day One | 2.46 | ||||
MREO | Mereo BioPharma | 2.53 | ||||
AMLX | Amylyx Pharmaceuticals | 5.51 | ||||
ABOS | Acumen Pharmaceuticals | 6.19 | ||||
ELDN | Eledon Pharmaceuticals | 6.84 | ||||
PDSB | PDS Biotechnology | 6.98 | ||||
INZY | Inozyme Pharma | 7.81 |
Check out Terns Pharmaceuticals Hype Analysis, Terns Pharmaceuticals Correlation and Terns Pharmaceuticals Performance. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.